936 results about "In vitro experiment" patented technology

The invention relates to a novel liver target drug carrier-glycyrrhetinic acid-polyethylene glycol/chitosan or chitosan derivative liver target compound drug delivery system. During the preparation of the nano-drug delivery system, the liver target small-molecule glycyrrhetinic acid is firstly used for modifying amino polyethylene glycol by the different sites, then a water soluble big-molecule liver target compound is prepared and is mixed with a solution containing chitosan or chitosan derivative by a certain proportion, an ion cross-linking agent is added under the stirring condition, and a target group is introduced at the same time of the spontaneous formation of nanoparticles by physical winding and electrostatic interaction. The method of introducing the target group of the invention is novel, the formation of spheres is simple, the conditions are moderate, and the content of the target group is high (the weight percentage of glycyrrhetinic acid is 5 to 30 percent). The drug delivery system has strong killing capacity to the cancer cells, the in vitro experiments show that the drug delivery system has very strong binding capacity with the liver cells, and the high content of the target group can improve the liver target capacity of the drug delivery system, realize the target positioning of the liver and open a new way for the treatment of liver cancer.

The invention relates to a multi-vesicular liposome, a blank multi-vesicular liposome and a preparation method and application thereof. The multi-vesicular liposome contains the following components in part by weight: 1 part of liposome, 0.01 to 20 parts of auxiliary emulsifier, 1 to 50 parts of osmotic pressure regulator and medicinal active ingredients; the medicament-to-lipid ratio of the multi-vesicular liposome is 1:(0.1-1):200; the lipid contains of a specific amount of neutral phospholipid, cholesterol and triglyceride; and the auxiliary emulsifier is selected from dextran, polyvinyl pyrrolidone, hydroxyethyl starch, gelatin, albumin, arginine and hydroxymethyl starch. The blank multi-vesicular liposome contains the following components in part by weight: 1 part of lipid, 0.01 to 20 parts of auxiliary emulsifier, 1 to 50 parts of osmotic pressure regulator and 0.1 to 50 parts of ion gradient regulator; the osmotic pressure of the in vivo water phase of the multi-vesicular liposome is equal to the osmotic pressure of human plasma; and the auxiliary emulsifier is as previously mentioned. The multi-vesicular liposome has high entrapment rate, and can achieve good sustained-release effect on in vivo and in vitro experiments.

The invention discloses a detecting micro-needle with a strengthened Raman and a fluorescence signal and a preparation method of the detecting micro-needle. The detecting micro-needle is characterized in that a medical acupuncture needle is used a basis for preparation. A metal nanometer material layer and a high molecular material layer with a strengthened Raman and a fluorescence signal cover the surfaces of the needle body and the needle tip part of the micro-needle. The detecting micro-needle structure comprises a micro-needle with a mercapto and amination surface, a metal nanoparticle layer and a high molecular material layer. The metal nanoparticles with a diameter of 20-1000nm coat the surface of the acupuncture needle by a covalent bond or a static adsorption effect. The high molecular layer covers the protecting metal nanoparticles in the outmost layer. Raman and fluorescence detection of in vitro samples and sampling and minimally invasive sampling and Raman and fluorescence detection in organism can be carried out based on the features of the detecting micro-needle. A novel rapid and super-sensitive detecting method for in vivo and in vitro experiment research, clinical diagnosis and large sample screening is provided by the invention.

The invention discloses a multifunctional multimode tumor-specific targeting phase-change nano-microsphere photoacoustic contrast medium, structurally comprising, from outside to inside, a ligand that is positioned on the surface of nano-microspheres and specifically binds with a tumor cell membrane surface receptor; the ligand is connected with shell membrane material through linker molecules, and the shell membrane material wraps photo-absorbers and phase-change molecules to the core. A preparation method of the medium includes: linking the ligand to the shell membrane material through the linker molecules by a 'five-step process' to prepare a targeting shell; wrapping the photo-absorbers and phase-change molecules to the core of the nano-microspheres by a special double-emulsification process, while making sure the targeting ligand is positioned on the surface of the nano-microspheres. In-vivo and in-vitro experiments indicate that the photoacoustic contrast medium may specifically bind with tumor cells to experience phase change; there are strong photoacoustic, ultrasonic and X-ray signals, and the medium is applicable to photoacoustic imaging, ultrasonic imaging and computed tomography.

The invention discloses a gene related to liver cancer and application thereof. Specifically, the gene is ENSG00000260285. According to the gene disclosed by the invention, up-regulated expression of the ENSG00000260285 in a liver cancer patient is found for the first time through high-throughput sequencing, and differential expression of the gene in the liver cancer patient is further verified by qPCR. Bioinformatic analysis finds that the ENSG00000260285 has higher accuracy when serving as a diagnosing marker of the liver cancer. According to the gene disclosed by the invention, in-vitro experiments find that restraining expression of the ENSG00000260285 can affect physiological characteristics of liver cancer cells, so that the gene can serve as a potential target to be applied to treating liver cancer.

The invention belongs to the technical field of medicines, and in particular relates to a compound taking thieno-pyrimidone as mother nuclide or a salt thereof, a preparation method and a combination of the compound and application of the compound used as a DPP-IV (dipeptidyl peptidase) inhibitor in preventing or treating diseases benefiting from the DPP-IV inhibition. The compound provided by the invention has the advantages that the preparation process is simple, the raw material is easily available, the compound is suitable for large-scale production, and in-vitro experiment verifies that the compound has good selective inhibition action on the DPP-IV, and hardly has any influence on the activities of DPP-VIII and DPP-IX while effectively inhibiting the activity of the DDP-IV, thereby predicting that the medicine prepared from the compound has very low toxicity and an outstanding advantage.

The invention discloses application of MYOZ1 in diagnosing and treating parkinsonism, belonging to the technical field of new application of genes. The experiment proves that the MYOZ1 gene expression in the blood of a parkinsonism patient is enhanced as compared with a normal person, which indicates that the MYOZ1 expression level in the blood can be detected to diagnose whether a subject suffers from parkinsonism. The in-vitro MTT experiment detect that the MYOZ1 gene expression is not beneficial to growth of human neuroblastoma cells. Therefore, the MYOZ1 has favorable development and application prospects in preparing products for diagnosing and treating parkinsonism.

The invention belongs to the field of pharmacy and relates to a D-configuration polypeptide and a gene delivery system of the D-configuration polypeptide and particularly relates to the D-configuration polypeptide which has high combining activity with neuropilin NRP-1 and has the brain tumor targeting and tumor tissue penetrating capabilities. The D-configuration polypeptide provided by the invention can mediate a nano delivery system to deliver drugs to tumors in a targeted manner for realizing targeted treatment of brain in-situ glioma. In vivo and in vitro experiments show that the genetic vector modified by the D-configuration polypeptide can remarkably improve the gene transfection efficiency. The genetic vector entrapping the therapeutic gene pORF-hTRAIL can remarkably prolong the lifetime of a nude mouse of brain glioma in-situ mode.

The present invention discloses the application of bakuchiol compound in preparing medicine for treating psychogenic diseases and neurogenic diseases. Extracorporeal experiment and animal experiment show that the bakuchiol compound can suppressing dopamine transport protein, noradrenalin transport protein and 5-hydroxy tryptamine transport protein selectively, and no influence on gamma-aminobutyric acid transport protein and L-glytamic acid transport protein, no cytotoxicity, and antidepressant effect higher than available antidepressant medicine amfebutamoe hydrochloride. Therefore, the bakuchiol compound has excellent marketability in preparing medicine for treating psychogenic diseases and neurogenic diseases.

The invention provides a preparation method of bispecific chimeric antigen receptor gene modified natural killer cells, comprising the features: constructing a bispecific chimeric antigen receptor gene containing specific-binding signaling lymphocyte activation molecule family member 7 and fibronectin mutants, recombining the bispecific chimeric antigen receptor gene to a viral vector, transfecting with human natural killer cells, and highly expressing the bispecific chimeric antigen receptor gene, thus specifically binding tumor cells that express the signaling lymphocyte activation molecule family member 7 and fibronectin mutants, inhibiting expression of natural killer cell inhibitory receptors, and preventing immune escape of tumor cells; meanwhile, activating a first signal and a co-stimulatory signal to trigger toxic activity of the tumor cells, and great anti-tumor killing toxicity is shown in in-vivo and in-vitro experiments; the invention also provides a kit for the preparation of autologous natural killer cells through the above method, and with the kit, it is possible to highly express the bispecific chimeric antigen receptor gene and trigger great anti-tumor effect.

The invention relates to a method for evaluating activity of a bio-feed. Concretely speaking, the invention relates to a method for evaluating activity of the bio-feed by taking intestinal flora as a target object, an aseptic animal is used for detecting the positive or negative fluctuation of the animal intestinal flora for through 16S rDNA sequencing, and the activity of the bio-feed is evaluated. The method can be used for evaluating activity of various bi-feeds, the effect of a detection substance by the intestinal flora can be detected through in-vivo and in-vitro experiment, and the superiority-inferiority of the sample can be reflected through flora fluctuation.

The invention discloses a method for promoting in-vitro and in-vivo degradation and cell extension adherence of alginate-based 3D printed bioink. The method comprises the following steps: step 1, adopting alginate as an extracellular matrix main body skeleton and constructing celliferous 3D bio-printed bioink; step 2, mixing alginate lyase with alginate-based bioink; step 3, adding cell suspensioninto the obtained bioink, choosing print parameters and printing out a 3D printing block through a 3D bio-printer; step 4, regulating and controlling in-vitro and after-transplantation-in-vivo degradation time and cell extension adherence degree of the 3D printing block through adjusting the concentration of the alginate lyase according to actual demands. The method disclosed by the invention canpromote the degradation and cell extension adherence of the bioink with the alginate as the skeleton under in-vivo and in-vitro environments, and enables the alginate 3D printed bioink to be adaptedto more in-vivo and in-vitro experiments and be better applied to soft tissue repairing and transplantation.

The invention provides bionic bleeding stopping biological glue with an amino acid sequence of SEQ ID NO:1. The invention also provides a bleeding stopping material which contains a protein with an amino acid sequence of SEQ ID NO:1 and sodium alginate modified by Dopa. The invention provides a product with bleeding stopping performance, and the product is prepared from polypeptide with an amino acid sequence SEQ ID NO:1 and a sodium alginate derivative; and application results show that the protein with the amino acid sequence of SEQ ID NO:1 can be used for improving ultramicrostructures, and in vitro experiments prove that the composite has good bleeding stopping effect.

The invention relates to a composition for interfering or treating diabetes and a preparation method of the composition. The composition comprises raw materials such as a DFEM culture medium (namely a medical and edible mushroom fermentation culture medium) and an edible mushroom fermentation seed liquid. The composition provided by the invention is definite in dose-effect for regulating the blood sugar level, and experiments in vitro show that the composition is higher in stability compared with the prior art.

The invention discloses a carrot seed antioxidant tripeptide as well as a preparation method and an application thereof. The sequence of the carrot seed antioxidant tripeptide is Tyr-Ser-Leu (YSL). The in-vitro experiment shows that DPPH and ABTS free radicals can be effectively removed by the tripeptide, and meanwhile the tripeptide is relatively good in stability. The carrot seed antioxidant tripeptide disclosed by the invention has the characteristics of simple structure, high antioxidant activity, and the like, can be used as assistant and substitute of an artificially synthesized antioxidant, and has important values for development and application of novel antioxidant healthcare products.

The invention discloses lactobacillus for producing lactic acid and H2O2 and an application of the lactobacillus. The lactobacillus is lactobacillus gasseri or lactobacillus crispatus, wherein the preservation number of the lactobacillus gasseri is CGMCC No. 15815 or CGMCC No. 15816; the preservation number of the lactobacillus crispatus is CGMCC No. 15813 or CGMCC No. 15814. The lactobacillus gasseri and lactobacillus crispatus provided by the invention have extremely strong lactic acid and H2O2 production ability, have good ability to adhere to vaginal epithelial cells, and can effectively inhibit reproduction of pathogenic bacteria like Gardner bacteria and Candida albicans in in-vivo and in-vitro experiments.

The invention discloses a preparation method of exosome and a stem cell proliferation reagent containing the exosome. The preparation method of the exosome comprises the steps that 1, a culture mediumwithout exosome serum is added bone marrow mesenchymal stem cells to dilute the bone marrow mesenchymal stem cells into a cell suspension, the cell suspension is inoculated into a cell culture bottleto be cultured, supernate obtained after culture is collected, and the exosome is extracted; 2, cell fragments, dead cells and impurities in the supernate are removed; the supernate is removed, thena phosphate buffer salt solution (PBS) is added to dissolve and collect exosome precipitate, the exosome precipitate is filtered through a sterile filter membrane, and the obtained exosome precipitateis packaged in a sterile centrifugal tube and stored for later use. According to the method, in-vitro experiments prove that the proliferation activity and related functions of the mesenchymal stem cells can be remarkably promoted by co-culturing the exosome secreted by the early-generation bone marrow mesenchymal stem cells and human umbilical cord mesenchymal stem cells, and the method is an effective strategy for potentially improving the function of cells in a large-scale cell culture process.

The invention provides novel polypeptin having potential value of biological control and medical applications, and a preparation method and application thereof. The structure of the polypeptin is shown as a formula (I). The invention has the advantages of providing the polypeptin which has the toxicity lower than that of polymyxin B and has the potential value of biological control and medical applications, and the preparation method and the application thereof. In vitro experiments show that the compound has the obvious effect of inhibiting all the tested gram-positive bacterium, gram-negative bacterium and fungi. Disk-culturing experiments show that the compound has certain effect of preventing and treating various fungal plant diseases and particularly has obvious effects of preventing and treating rice sheath blight.

Provided is yarn for a cell culture scaffold. The yarn includes ply-twisted fiber strands, and to prevent density-dependent inhibition of cultured cells and increase a cell-contacting specific surface area, at least a part of the plurality of twisted fiber strands are untwisted such that an open space is formed between the fibers. A cell proliferation rate and cell viability may be increased by creating microenvironments suitable for migration, proliferation and differentiation of the cultured cells using the yarn. A large quantity of cells may be simultaneously cultured by creating a cell proliferation space as large as possible in a scaffold space having a limited cell proliferation space, and cell proliferation may be steadily maintained by preventing the inhibition of cell proliferation due to intercellular contact. The cells cultured may be cultured to have a shape/structure suitable for application to an in vitro experiment model or implantation into an animal body.

The invention discloses antifungal application of fraxetin, belonging to the technical field of medicines. In-vitro experiments show that fraxetin has relatively good inhibition effect to the fungi, is capable of restoring the effect of an antifungal drug, namely fluconazole to drug-resistant fungi and therefore can be taken as the antifungal drug and a synergist for the antifungal drug. Accordingto the antifungal application, the new use of fraxetin is opened up, fraxetin is used as the antifungal drug and the synergist for the antifungal drug, a new candidate drug is provided for the fungustreatment, and the antifungal effects of existing drugs are improved. Under the conditions that clinical fungus drug resistance becomes common increasingly and the drug resistance level becomes serious increasingly, the effect of an antifungal drug to the drug-resistant fungi is restored, and the use dosage of the antifungal drug is reduced, so that the medical expense of a patient is saved, andthe toxic and side effects of the drugs are reduced.

The invention discloses a traditional Chinese medicine composition for treating gastric cancer. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 10-20 parts of pilose asiabell root, 15-35 parts of fresh rhizoma atractylodis macrocephalae, 10-20 parts of zedoary, 10-15 parts of rhizoma pinelliae preparata, 10-30 parts of Chinese actinidia root and 10-30 parts of rhodiola rosea. The traditional Chinese medicine composition exerts advantages of comprehensive therapy of traditional Chinese medicine, and dialectics is combined with differentiation of disease; and according to etiology, pathogenesis and pathology features of gastric cancer, experimental observation on an in-vitro experiment for inhibiting gastric cancer SGC7901 cell proliferation by medicines and an in-vivo experiment for inhibiting transplanted tumor of gastric cancer SGC7901 cells in nude mice by medicines shows that the traditional Chinese medicine composition in the invention can induce the SGC7901 cells to produce autophagy so as to inhibit the proliferation of the gastric cancer SGC7901 cells, thereby opening a road for hope for treating patients with gastric cancer.